India's Richest People 2026 edition · 1 director · Source: Hurun India
- #1,090 Ramesh Babu Potluri & family ₹2,400 Cr
Market Cap
₹4,453 Cr
SMSPHARMA · NSE
Share Price
₹485.80
+2.18% today
Revenue
₹887 Cr
FY 2025-26 · +13.3% YoY
EBITDA
₹171 Cr
Margin 19.3%
Net Profit
₹102 Cr
FY 2025-26 · +47.5% YoY
P/E (TTM)
40.5x
P/B 5.3x
Authorised capital
₹12 Cr
Registered with MCA
Paid-up capital
₹9.37 Cr
Issued & subscribed
About SMS Pharmaceuticals Limited
Data last updated:
SMS Pharmaceuticals Limited is a public limited company based in Hyderabad, Telangana, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 14 December 1987 and has been in existence for over 39 years.
Its director Ramesh Babu Potluri and family are #1,090 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L24239TG1987PLC008066. Its GSTIN is 36AADCS2221D1ZX (Telangana). The company holds 4 GST registrations, of which 3 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 532815 and NSE: SMSPHARMA.
The company has an authorised share capital of ₹12 Cr and a paid-up capital of ₹9.37 Cr. It was formerly known as S.M.S. Pharmaceuticals Private Limited and Sms Pharmaceuticals Pvt Limited. It is led by directors including Ramesh Babu Potluri (Managing Director) and Vamsi Krishna Potluri (Whole-Time Director).
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 8th Floor Trendset Jayabheri Connect, Hyderabad, Telangana, India – 500084.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹886.87 Cr, a growth of 13.3% compared to the previous year. For the same year it recorded a net profit of ₹101.98 Cr (net margin 11.5%) and EBITDA of ₹171.28 Cr (EBITDA margin 19.3%). The net worth stands at ₹785.81 Cr (up 22.8% YoY). Total assets are valued at ₹1,152.06 Cr (up 21.1% YoY).
The company has about 1,193 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Sms Pharmaceuticals. As per MCA filings, the company has open charges of ₹814.83 Cr and satisfied charges of ₹652 Cr on record. Court records list 81 cases involving the company, including 46 filed by the company and 35 filed against it; 11 cases are pending. The company has 52 deals on record (50 market trades, 1 acquisition, 1 ipo); the latest was in November 2025. Its 8 peer companies in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Virupaksha Organics Limited with revenue of ₹816.52 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website smspharma.com.
Company details
CIN L24239TG1987PLC008066
Registration Number 008066
Incorporation Date 14 December 1987
ROC Hyderabad
Listing Status Listed - Listed on NSE (SMSPHARMA); Listed on BSE (532815)
Company Status Active
Date of Last AGM 29 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
Name history
SMS Pharmaceuticals has undergone 2 name changes throughout its history. The company was previously known as S.M.S. Pharmaceuticals Private Limited, and Sms Pharmaceuticals Pvt Limited. The current legal name is Sms Pharmaceuticals Limited.
| Company Name | Status |
|---|---|
| SMS Pharmaceuticals Limited | Current |
| S.M.S. Pharmaceuticals Private Limited | Previous |
| Sms Pharmaceuticals Pvt Limited | Previous |
CIN history
SMS Pharmaceuticals has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24239TG1987PLC008066, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24239TG1987PLC008066 | Current |
| U24239AP1987PLC008066 | Previous |
| L24239AP1987PLC008066 | Previous |
Key People
Ramesh Babu Potluri Managing Director Vamsi Krishna Potluri Whole-Time Director Shravan Kudaravalli Director Recognitions & Rankings of SMS Pharmaceuticals
Contact details
SMS Pharmaceuticals Limited's registered office is in Serilingampally, Telangana. Its website is smspharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address8th Floor Trendset Jayabheri Connect, Hyderabad, Telangana, India – 500084
- IndustryPharma, API Manufacturers
To see the full contact details of SMS Pharmaceuticals Limited, buy the company report.
Comprehensive company report
SMS Pharmaceuticals Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
SMS Pharmaceuticals operates one associated brand: Sms Pharmaceuticals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Active pharmaceutical ingredients and intermediates are manufactured by SMS Pharmaceuticals. | smspharma.com |
Business activity
The main business activity of SMS Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of SMS Pharmaceuticals Limited, buy the company report.
Financials of SMS Pharmaceuticals Limited
FY 2025-26 filings availableSMS Pharmaceuticals Limited reported revenue of ₹886.87 Cr (up 13.3% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹887 Cr
+13.3% YoY
EBITDA
₹171 Cr
+23.2% YoY
Profit After Tax
₹102 Cr
+47.5% YoY
Net Worth
₹786 Cr
+22.8% YoY
Total Assets
₹1,152 Cr
+21.1% YoY
Total Debt
₹365 Cr
+17.5% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 887 | 783 | 709 | 522 | 520 | 563 | 412 |
| Revenue growth | +13.3% | +10.4% | +35.9% | +0.4% | -7.7% | +36.7% | - |
| EBITDA | 171 | 139 | 117 | 54.55 | 115 | 121 | 80.03 |
| EBITDA margin | +19.3% | +17.8% | +16.5% | +10.5% | +22.1% | +21.5% | +19.4% |
| Profit before tax | 117 | 92.33 | 66.11 | 5.36 | 68.50 | 91.12 | 50.75 |
| Net profit | 102 | 69.12 | 49.80 | (7.01) | 62.22 | 62.53 | 31.60 |
| Net profit margin | +11.5% | +8.8% | +7.0% | -1.3% | +12.0% | +11.1% | +7.7% |
| EPS (₹) | 11.15 | 7.80 | 5.89 | (0.83) | 7.35 | 7.39 | 3.73 |
| Balance sheet | |||||||
| Total assets | 1,152 | 952 | 818 | 716 | 735 | 667 | 507 |
| Net worth | 786 | 640 | 536 | 461 | 470 | 411 | 348 |
| Total debt | 365 | 311 | 281 | 254 | 263 | 255 | 157 |
| Cash & bank | 46.07 | 41.59 | 36.20 | 7.47 | 46.66 | 40.51 | 9.65 |
| Net working capital | 478 | 401 | 361 | 288 | 292 | 218 | 158 |
| Cash flow | |||||||
| Cash from operations | 59.22 | 81.71 | 50.12 | 22.45 | 45.06 | 90.45 | 39.71 |
| Cash from investing | (131) | (123) | (52.07) | (29.76) | (27.15) | (152) | (42.56) |
| Cash from financing | 76.03 | 47.08 | 30.68 | (31.97) | (11.75) | 92.02 | (2.40) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 207 | 238 | 210 | 242 | 196 | 248 | 173 | 197 |
| Revenue growth (YoY) | +5.6% | -4.1% | +21.4% | +23.2% | +19.2% | - | - | - |
| Other income | 1.74 | 2.57 | 3.75 | 1.43 | 0.59 | 1.42 | 2.13 | 1.30 |
| EBITDA | 40.95 | 39.90 | 43.65 | 48.37 | 39.37 | 40.81 | 33.21 | 31.47 |
| EBITDA margin | +19.8% | +16.8% | +20.7% | +20.0% | +20.1% | +16.4% | +19.2% | +16.0% |
| Depreciation | 9.99 | 10.13 | 10.02 | 10.02 | 9.75 | 8.64 | 8.70 | 8.62 |
| Interest | 5.50 | 5.28 | 6.22 | 5.74 | 5.84 | 5.07 | 4.20 | 4.61 |
| Profit before tax | 27.20 | 27.06 | 31.16 | 34.04 | 24.37 | 28.52 | 22.44 | 19.54 |
| Tax | 7.00 | 6.10 | 7.97 | 8.91 | 5.65 | 8.44 | 5.36 | 5.68 |
| Net profit | 20.20 | 20.96 | 23.19 | 25.13 | 18.72 | 20.08 | 17.08 | 13.86 |
| EPS (₹) | 2.23 | 3.58 | 2.59 | 2.84 | 2.31 | 2.40 | 2.15 | 1.67 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 887 | 783 | 709 | 522 | 520 | 563 | 412 |
| Revenue growth | +13.3% | +10.4% | +35.9% | +0.4% | -7.7% | +36.7% | - |
| EBITDA | 171 | 140 | 117 | 54.75 | 115 | 121 | 80.03 |
| EBITDA margin | +19.3% | +17.9% | +16.5% | +10.5% | +22.1% | +21.5% | +19.4% |
| Profit before tax | 116 | 93.30 | 66.33 | 5.56 | 68.65 | 91.12 | 50.75 |
| Net profit | 87.60 | 68.35 | 49.39 | 4.13 | 68.03 | 60.97 | 32.71 |
| Net profit margin | +9.9% | +8.7% | +7.0% | +0.8% | +13.1% | +10.8% | +7.9% |
| EPS (₹) | 9.58 | 7.71 | 5.84 | 0.48 | 8.04 | 7.20 | 3.86 |
| Balance sheet | |||||||
| Total assets | 1,171 | 985 | 852 | 751 | 759 | 685 | 526 |
| Net worth | 805 | 673 | 570 | 495 | 494 | 428 | 367 |
| Total debt | 365 | 311 | 281 | 254 | 263 | 255 | 157 |
| Cash & bank | 45.98 | 41.58 | 36.20 | 7.47 | 46.66 | 40.51 | 9.65 |
| Net working capital | 477 | 401 | 361 | 288 | 292 | 218 | 158 |
| Cash flow | |||||||
| Cash from operations | 60.68 | 81.71 | 50.12 | 22.45 | 45.06 | 90.45 | 39.71 |
| Cash from investing | (132) | (123) | (52.07) | (29.76) | (27.15) | (152) | (42.56) |
| Cash from financing | 76.03 | 47.08 | 30.68 | (31.97) | (11.75) | 92.02 | (2.40) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 207 | 238 | 210 | 242 | 196 | 248 | 173 | 197 |
| Revenue growth (YoY) | +5.6% | -4.1% | +21.4% | +23.2% | +19.2% | - | - | - |
| Other income | 1.74 | 2.57 | 3.75 | 1.43 | 0.59 | 1.42 | 2.13 | 1.30 |
| Total expenses | 165 | 198 | 167 | 194 | 157 | 207 | 140 | 165 |
| EBITDA | 41.89 | 39.88 | 43.80 | 48.38 | 38.86 | 41.35 | 33.30 | 31.86 |
| EBITDA margin | +20.2% | +16.8% | +20.8% | +20.0% | +19.8% | +16.7% | +19.2% | +16.2% |
| Depreciation | 9.99 | 10.13 | 10.02 | 10.02 | 9.75 | 8.64 | 8.70 | 8.62 |
| Interest | 5.50 | 5.28 | 6.22 | 5.74 | 5.84 | 5.07 | 4.20 | 4.61 |
| Profit before tax | 28.14 | 27.04 | 31.31 | 34.05 | 23.86 | 29.06 | 22.53 | 19.93 |
| Tax | 7.01 | 6.12 | 7.97 | 8.91 | 5.65 | 8.44 | 5.36 | 5.68 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 29 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 207 | 238 | 210 | 242 | 196 | 248 | 173 | 197 |
| Revenue growth (YoY) | +5.6% | -4.1% | +21.4% | +23.2% | +19.2% | - | - | - |
| Other income | 1.74 | 2.57 | 3.75 | 1.43 | 0.59 | 1.42 | 2.13 | 1.30 |
| EBITDA | 40.95 | 39.90 | 43.65 | 48.37 | 39.37 | 40.81 | 33.21 | 31.47 |
| EBITDA margin | +19.8% | +16.8% | +20.7% | +20.0% | +20.1% | +16.4% | +19.2% | +16.0% |
| Depreciation | 9.99 | 10.13 | 10.02 | 10.02 | 9.75 | 8.64 | 8.70 | 8.62 |
| Interest | 5.50 | 5.28 | 6.22 | 5.74 | 5.84 | 5.07 | 4.20 | 4.61 |
| Profit before tax | 27.20 | 27.06 | 31.16 | 34.04 | 24.37 | 28.52 | 22.44 | 19.54 |
| Tax | 7.00 | 6.10 | 7.97 | 8.91 | 5.65 | 8.44 | 5.36 | 5.68 |
| Net profit | 20.20 | 20.96 | 23.19 | 25.13 | 18.72 | 20.08 | 17.08 | 13.86 |
| EPS (₹) | 2.23 | 3.58 | 2.59 | 2.84 | 2.31 | 2.40 | 2.15 | 1.67 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 887 | 783 | 709 | 522 | 520 | 563 | 412 |
| Revenue growth | +13.3% | +10.4% | +35.9% | +0.4% | -7.7% | +36.7% | - |
| Other income | 8.35 | 6.22 | 4.46 | 4.91 | 5.20 | 3.45 | 5.11 |
| Total expenses | 716 | 644 | 592 | 468 | 405 | 442 | 332 |
| Employee cost | 0.00 | 80.08 | 64.15 | 50.08 | 51.02 | 41.17 | 39.35 |
| EBITDA | 171 | 139 | 117 | 54.55 | 115 | 121 | 80.03 |
| EBITDA margin | +19.3% | +17.8% | +16.5% | +10.5% | +22.1% | +21.5% | +19.4% |
| Depreciation | 39.92 | 34.34 | 31.52 | 32.13 | 32.15 | 22.28 | 22.07 |
| Interest | 23.08 | 18.54 | 23.60 | 21.97 | 19.16 | 11.19 | 12.32 |
| Profit before tax | 117 | 92.33 | 66.11 | 5.36 | 68.50 | 91.12 | 50.75 |
| Tax | 28.64 | 24.94 | 16.91 | 1.47 | 0.62 | 30.16 | 18.07 |
| Net profit | 102 | 69.12 | 49.80 | (7.01) | 62.22 | 62.53 | 31.60 |
| Net profit margin | +11.5% | +8.8% | +7.0% | -1.3% | +12.0% | +11.1% | +7.7% |
| EPS (₹) | 11.15 | 7.80 | 5.89 | (0.83) | 7.35 | 7.39 | 3.73 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 9.37 | 8.87 | 8.47 | 8.47 | 8.47 | 8.47 | 8.47 |
| Reserves & surplus | 776 | 615 | 499 | 452 | 462 | 402 | 340 |
| Shareholders' funds (net worth) | 786 | 640 | 536 | 461 | 470 | 411 | 348 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 364 | 310 | 279 | 289 | 259 | 249 | 151 |
| Unsecured loans | 1.20 | 1.20 | 1.79 | (34.84) | 4.35 | 5.26 | 5.98 |
| Total debt | 365 | 311 | 281 | 254 | 263 | 255 | 157 |
| Total liabilities | 1,152 | 952 | 818 | 716 | 735 | 667 | 507 |
| Assets | |||||||
| Gross block | 801 | 760 | 631 | 576 | 571 | 559 | 361 |
| Net block | 534 | 533 | 437 | 412 | 438 | 457 | 280 |
| Capital work in progress | 122 | 34.67 | 30.27 | 33.19 | 11.00 | 6.74 | 42.12 |
| Investments | 26.28 | 11.68 | 10.94 | 10.52 | 21.53 | 27.30 | 25.81 |
| Inventories | 351 | 285 | 234 | 224 | 251 | 138 | 129 |
| Sundry debtors | 216 | 203 | 236 | 148 | 48.52 | 106 | 48.77 |
| Cash & bank balances | 46.07 | 41.59 | 36.20 | 7.47 | 46.66 | 40.51 | 9.65 |
| Loans & advances | 24.86 | 24.92 | 27.76 | 31.33 | 30.78 | 25.35 | 31.16 |
| Total current assets | 638 | 554 | 534 | 411 | 377 | 309 | 219 |
| Total current liabilities | 160 | 153 | 173 | 123 | 84.83 | 91.41 | 61.13 |
| Net working capital | 478 | 401 | 361 | 288 | 292 | 218 | 158 |
| Total assets | 1,152 | 952 | 818 | 716 | 735 | 667 | 507 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 41.40 | 36.04 | 7.31 | 46.58 | 40.42 | 9.54 | 14.80 |
| Net cash from operating activities | 59.22 | 81.71 | 50.12 | 22.45 | 45.06 | 90.45 | 39.71 |
| Net cash from investing activities | (131) | (123) | (52.07) | (29.76) | (27.15) | (152) | (42.56) |
| Net cash from financing activities | 76.03 | 47.08 | 30.68 | (31.97) | (11.75) | 92.02 | (2.40) |
| Net change in cash | 4.48 | 5.36 | 28.73 | (39.28) | 6.16 | 30.88 | (5.25) |
| Closing cash | 46.07 | 41.59 | 36.20 | 7.47 | 46.66 | 40.51 | 9.65 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +13.3% | +10.4% | +35.9% | +0.4% | -7.7% | +36.7% | - |
| EBITDA growth | +23.2% | +19.0% | +114.1% | -52.4% | -5.4% | +51.4% | - |
| PBT growth | +26.3% | +39.7% | +1133.4% | -92.2% | -24.8% | +79.6% | -18.6% |
| Net income growth | +47.5% | +38.8% | +810.4% | -111.3% | -0.5% | +97.9% | - |
| Revenue CAGR (3Y) | +19.3% | +14.6% | +8.0% | +8.2% | +3.8% | +6.8% | -2.0% |
| EBITDA CAGR (3Y) | +46.4% | +6.6% | -1.2% | -12.0% | +8.3% | +9.1% | +2.1% |
| Profitability & leverage | |||||||
| Net income margin | +9.9% | +8.6% | +6.9% | +0.8% | +13.1% | +10.8% | +7.9% |
| Return on capital employed | - | +12.5% | +11.7% | +3.8% | +12.5% | +17.4% | +13.0% |
| Return on net worth | - | +11.5% | +9.9% | +0.8% | +15.4% | +16.1% | +9.8% |
| Debt / equity | - | 0.50 | 0.54 | 0.56 | 0.59 | 0.54 | 0.45 |
| Long-term debt / equity | - | 0.22 | 0.28 | 0.33 | 0.34 | 0.29 | 0.20 |
| Interest cover | 17.57 | 17.72 | 27.68 | 97.99 | 23.24 | 11.32 | 21.26 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 1.20 | 1.25 | 0.97 | 0.98 | 1.33 | 1.29 |
| Inventory turnover | - | 3.22 | 3.29 | 2.34 | 2.86 | 4.58 | 3.41 |
| Debtors turnover | - | 3.80 | 3.91 | 5.63 | 7.20 | 7.92 | 12.12 |
| EPS (₹) | 11.15 | 7.80 | 5.89 | (0.83) | 7.35 | 7.39 | 3.73 |
| Dividend per share (₹) | 0.40 | 0.40 | 0.40 | 0.30 | 0.30 | 0.30 | 0.25 |
| Book value per share (₹) | 0.00 | 70.36 | 59.98 | 54.40 | 55.56 | 48.50 | 41.14 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 207 | 238 | 210 | 242 | 196 | 248 | 173 | 197 |
| Revenue growth (YoY) | +5.6% | -4.1% | +21.4% | +23.2% | +19.2% | - | - | - |
| Other income | 1.74 | 2.57 | 3.75 | 1.43 | 0.59 | 1.42 | 2.13 | 1.30 |
| Total expenses | 165 | 198 | 167 | 194 | 157 | 207 | 140 | 165 |
| EBITDA | 41.89 | 39.88 | 43.80 | 48.38 | 38.86 | 41.35 | 33.30 | 31.86 |
| EBITDA margin | +20.2% | +16.8% | +20.8% | +20.0% | +19.8% | +16.7% | +19.2% | +16.2% |
| Depreciation | 9.99 | 10.13 | 10.02 | 10.02 | 9.75 | 8.64 | 8.70 | 8.62 |
| Interest | 5.50 | 5.28 | 6.22 | 5.74 | 5.84 | 5.07 | 4.20 | 4.61 |
| Profit before tax | 28.14 | 27.04 | 31.31 | 34.05 | 23.86 | 29.06 | 22.53 | 19.93 |
| Tax | 7.01 | 6.12 | 7.97 | 8.91 | 5.65 | 8.44 | 5.36 | 5.68 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 887 | 783 | 709 | 522 | 520 | 563 | 412 |
| Revenue growth | +13.3% | +10.4% | +35.9% | +0.4% | -7.7% | +36.7% | - |
| Other income | 8.35 | 6.22 | 4.46 | 4.91 | 5.20 | 3.45 | 5.11 |
| Total expenses | 716 | 643 | 592 | 467 | 405 | 442 | 332 |
| Employee cost | 0.00 | 69.72 | 56.78 | 50.08 | 51.02 | 41.17 | 39.35 |
| EBITDA | 171 | 140 | 117 | 54.75 | 115 | 121 | 80.03 |
| EBITDA margin | +19.3% | +17.9% | +16.5% | +10.5% | +22.1% | +21.5% | +19.4% |
| Depreciation | 39.92 | 34.34 | 31.52 | 32.13 | 32.15 | 22.28 | 22.07 |
| Interest | 23.08 | 18.54 | 23.60 | 21.97 | 19.16 | 11.19 | 12.32 |
| Profit before tax | 116 | 93.30 | 66.33 | 5.56 | 68.65 | 91.12 | 50.75 |
| Tax | 28.66 | 24.94 | 16.91 | 1.47 | 0.62 | 30.16 | 18.07 |
| Net profit | 87.60 | 68.35 | 49.39 | 4.13 | 68.03 | 60.97 | 32.71 |
| Net profit margin | +9.9% | +8.7% | +7.0% | +0.8% | +13.1% | +10.8% | +7.9% |
| EPS (₹) | 9.58 | 7.71 | 5.84 | 0.48 | 8.04 | 7.20 | 3.86 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 9.37 | 8.87 | 8.47 | 8.47 | 8.47 | 8.47 | 8.47 |
| Reserves & surplus | 795 | 648 | 533 | 487 | 485 | 420 | 359 |
| Shareholders' funds (net worth) | 805 | 673 | 570 | 495 | 494 | 428 | 367 |
| Secured loans | 364 | 310 | 279 | 289 | 259 | 249 | 151 |
| Unsecured loans | 1.20 | 1.20 | 1.79 | (34.84) | 4.35 | 5.26 | 5.98 |
| Total debt | 365 | 311 | 281 | 254 | 263 | 255 | 157 |
| Total liabilities | 1,171 | 985 | 852 | 751 | 759 | 685 | 526 |
| Assets | |||||||
| Gross block | 801 | 760 | 631 | 576 | 571 | 559 | 361 |
| Net block | 534 | 533 | 437 | 412 | 438 | 457 | 280 |
| Capital work in progress | 116 | 34.67 | 30.27 | 33.19 | 11.00 | 6.74 | 42.12 |
| Investments | 52.11 | 45.11 | 45.10 | 45.10 | 45.00 | 45.00 | 45.00 |
| Inventories | 351 | 285 | 234 | 224 | 251 | 138 | 129 |
| Sundry debtors | 216 | 203 | 236 | 148 | 48.52 | 106 | 48.77 |
| Cash & bank balances | 45.98 | 41.58 | 36.20 | 7.47 | 46.66 | 40.51 | 9.65 |
| Loans & advances | 23.75 | 24.92 | 27.76 | 31.33 | 30.78 | 25.35 | 31.16 |
| Total current assets | 637 | 554 | 534 | 411 | 377 | 309 | 219 |
| Total current liabilities | 159 | 153 | 173 | 123 | 84.83 | 91.41 | 61.13 |
| Net working capital | 477 | 401 | 361 | 288 | 292 | 218 | 158 |
| Total assets | 1,171 | 985 | 852 | 751 | 759 | 685 | 526 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 41.39 | 36.04 | 7.31 | 46.58 | 40.42 | 9.54 | 14.80 |
| Net cash from operating activities | 60.68 | 81.71 | 50.12 | 22.45 | 45.06 | 90.45 | 39.71 |
| Net cash from investing activities | (132) | (123) | (52.07) | (29.76) | (27.15) | (152) | (42.56) |
| Net cash from financing activities | 76.03 | 47.08 | 30.68 | (31.97) | (11.75) | 92.02 | (2.40) |
| Net change in cash | 4.39 | 5.35 | 28.73 | (39.28) | 6.16 | 30.88 | (5.25) |
| Closing cash | 45.98 | 41.58 | 36.20 | 7.47 | 46.66 | 40.51 | 9.65 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +13.3% | +10.4% | +35.9% | +0.4% | -7.7% | +36.7% | - |
| EBITDA growth | +22.1% | +19.6% | +113.7% | -52.3% | -5.3% | +51.4% | - |
| PBT growth | +24.6% | +40.7% | +1093.0% | -91.9% | -24.7% | +79.6% | -18.6% |
| Net income growth | +28.2% | +38.4% | +1095.9% | -93.9% | +11.6% | +86.4% | - |
| Revenue CAGR (3Y) | +19.3% | +14.6% | +8.0% | +8.2% | +3.8% | +6.8% | -2.0% |
| EBITDA CAGR (3Y) | +46.2% | +6.8% | -1.2% | -11.9% | +8.4% | +9.1% | +2.1% |
| Profitability & leverage | |||||||
| Net income margin | +9.9% | +8.7% | +7.0% | +0.8% | +13.1% | +10.8% | +7.9% |
| Return on capital employed | - | +12.2% | +11.2% | +3.7% | +12.2% | +16.9% | +12.5% |
| Return on net worth | - | +11.0% | +9.3% | +0.8% | +14.8% | +15.3% | +9.2% |
| Debt / equity | - | 0.48 | 0.50 | 0.52 | 0.56 | 0.52 | 0.43 |
| Long-term debt / equity | - | 0.21 | 0.26 | 0.31 | 0.33 | 0.28 | 0.19 |
| Interest cover | 17.62 | 17.55 | 27.61 | 97.13 | 23.19 | 11.32 | 21.26 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 1.20 | 1.25 | 0.97 | 0.98 | 1.33 | 1.29 |
| Inventory turnover | - | 3.22 | 3.29 | 2.34 | 2.86 | 4.58 | 3.41 |
| Debtors turnover | - | 3.80 | 3.91 | 5.63 | 7.20 | 7.92 | 12.12 |
| EPS (₹) | 9.58 | 7.71 | 5.84 | 0.48 | 8.04 | 7.20 | 3.86 |
| Dividend per share (₹) | 0.40 | 0.40 | 0.40 | 0.30 | 0.30 | 0.30 | 0.25 |
| Book value per share (₹) | 0.00 | 74.13 | 64.02 | 58.49 | 58.33 | 50.59 | 43.40 |
To see the full year-wise statements and ratios of SMS Pharmaceuticals Limited, buy the company report.
Board of directors of SMS Pharmaceuticals Limited
SMS Pharmaceuticals has 8 current directors and 20 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Shravan Kudaravalli Also directs: CMH Tools Limited | Director | 26 May 2018 | 8 Years 5 Months | Current |
| Srinivas Sarvepalli | Director | 12 Aug 2019 | 7 Years 2 Months | Current |
| Ramesh Babu Potluri Also directs: Potluri Agri Farms LLP, SMS Peptides Private Limited, VKT Pharma Private Limited and 1 more | Managing Director | 01 Dec 2008 | 17 Years 10 Months | Current |
| Vamsi Krishna Potluri Also directs: SMS Peptides Private Limited, VKT Pharma Private Limited, Potluri Infra Projects LLP and 3 more | Whole-Time Director | 05 Jun 2020 | 6 Years 4 Months | Current |
| Suresh Kumar Gangavarapu | Director | 12 Aug 2024 | 2 Years 2 Months | Current |
| Shanti Sree Bolleni | Director | 12 Aug 2024 | 2 Years 2 Months | Current |
Showing 6 of 8 current directors. View all directors
Peer comparison
SMS Pharmaceuticals Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| SMS Pharmaceuticals Limitedthis company | ₹886.87 Cr (FY 2026) | ₹101.98 Cr | 11.5% | 13.3% | 1,193 | Hyderabad, Telangana, India |
| Virupaksha Organics Limited | ₹816.52 Cr (FY 2025) | 6.0% | Hyderabad, Telangana, India | |||
| Symed Labs Limited | ₹791.92 Cr (FY 2025) | 6.0% | Hyderabad, Telangana, India | |||
| Synokem Pharmaceuticals Limited | ₹791.15 Cr (FY 2025) | 0.0% | New Delhi, Delhi, India | |||
| Sterile India Private Limited | ₹791.14 Cr (FY 2025) | -13.0% | New Delhi, Delhi, India | |||
| Prime Pharmaceuticals Private Limited | ₹783.06 Cr (FY 2025) | 131.0% | Mumbai, Maharashtra, India | |||
| Symbiotec Pharmalab Limited | ₹755.98 Cr (FY 2025) | 5.0% | Mhow, Madhya Pradesh, India | |||
| Tagoor Laboratories Private Limited | ₹719.28 Cr (FY 2022) | 55.0% | Andhra Pradesh, India | |||
| Optimus Drugs Private Limited | ₹713.55 Cr (FY 2024) | -41.0% | Hyderabad, Telangana, India |
To see the full peer comparison of SMS Pharmaceuticals Limited, buy the company report.
Auditor
SMS Pharmaceuticals Limited is audited by SURYANARAYANA & SURESH for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| SURYANARAYANA & SURESH | FY 2024 | 006631S |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 68.10%, foreign institutional investors hold 0.60%, domestic institutional investors hold 2.90% and retail and other public shareholders hold 28.40%.
Sep 2026
QUARTER
68.10% Promoters
2.90% DII (Domestic Institutional)
0.60% FII (Foreign Institutional)
28.40% Retail & Others
Promoter holding - history
Now 68.10% · Sep 2026High 68.10% · Dec 2025Low 68.10% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 68.10% | 68.10% | 68.10% | 68.10% |
| Public | 31.90% | 31.90% | 31.90% | 31.90% |
Charges & borrowings
Open charges
₹814.83 Cr
Satisfied charges
₹652 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 24 Feb 2026 | 101242646 | Others | ₹180 Cr | Open | |
| 22 Oct 2025 | 101182903 | Axis Bank Limited | ₹40 Cr | Open | |
| 14 Feb 2024 | 100866272 | Others | ₹100 Cr | Open | |
| 24 Jan 2023 | 100677606 | Idbi Bank Limited | ₹25 Cr | Open | |
| 08 Mar 2022 | 100544606 | Others | ₹16.09 Cr | Open |
To see the full charge records of SMS Pharmaceuticals Limited, buy the company report.
Total charge records: 64 View all charges
Deals & funding
SMS Pharmaceuticals Limited has 52 deals on record (50 market trades, 1 acquisition, 1 ipo); the latest was in November 2025.
Total deals
52
Market trades
50
Acquisition
1
IPO
1
Deals on record (5 of 52)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2025 | Market trade | ₹62.04 Cr | Buyer: Musigma Securities, Graviton Research Capital LLP , NK Securities Research Private Limited Seller: Musigma Securities, Graviton Research Capital LLP , NK Securities Research Private Limited |
| Sep 2024 | Market trade | ₹24.9 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Mar 2024 | Market trade | ₹10.06 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Mar 2024 | Market trade | ₹10.39 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Mar 2024 | Market trade | ₹8.49 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
To see the full deal history of SMS Pharmaceuticals Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
SMS Pharmaceuticals Limited has 81 court cases on record: 46 filed by SMS Pharmaceuticals, 35 filed against it. 11 cases are pending and 70 are disposed.
Total cases
81
Filed by the company
46
Filed against the company
35
Pending
11
Disposed
70
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 55 | 18 | 5 |
| District courts | 24 | 16 | 6 |
| Supreme Court | 2 | 1 | 0 |
Cases on record (5 of 81)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, New Delhi, Delhi | Court case (Counter Claim) | Filed against the company by Fresenius Kabi Oncology Ltd. | Pending |
| District court, New Delhi, Delhi | Civil suit | Filed against the company by Fresenius Kabi Oncology Ltd. | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Court case (SS CASES S) | Filed against the company by M-S Krishna Solvechem Ltd | Pending |
| High Court, TELANGANA | Writ petition | Filed by the company against M/S. Ramky Pharma City (India) Limited, and 2 others | Pending |
| High Court of Delhi | Appeal | Filed by the company against M/S Fresenius Kabi Oncology Ltd | Disposed |
To see the full case history of SMS Pharmaceuticals Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
SMS Pharmaceuticals Limited was last rated by Care on 03 Sep 2021.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 03 Sep 2021 |
To see the full credit ratings and regulatory alerts of SMS Pharmaceuticals Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for SMS Pharmaceuticals Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
SMS Pharmaceuticals has 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
1
Associated companies
Employees & EPFO
SMS Pharmaceuticals Limited has a workforce of 1,193 employees on its EPFO records as of Mar 23, 2024, across 2 active EPFO establishments.
Employee count
1,193
Active EPFO establishments
2
Employee growth
8.55%
GST
SMS Pharmaceuticals has 4 GST registrations: 3 active and 1 cancelled or inactive.
Total GSTINs
4
Active
3
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AADCS2221D1ZX | Telangana | Active | 01 Jul 2017 |
| 36AADCS2221D2ZW | Telangana | Active | 25 Jul 2017 |
| 37AADCS2221D1ZV | Andhra Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of SMS Pharmaceuticals Limited, buy the company report.
Recent activity
SMS Pharmaceuticals Limited has 40 board changes on record since 1994: 24 appointments and 16 cessations. The latest: Shanti Sree Bolleni was appointed as Director on 12 Aug 2024.
Charges
A charge with Others of Rs. 80.00 Cr registered on 24 Jun 2016 with Charge ID 100035079 was modified on 15 Sep 2026.
Charges
A charge with Others of Rs. 180.00 Cr registered on 24 Feb 2026 with Charge ID 101242646 was modified on 09 Sep 2026.
Charges
A charge registered on 30 Jun 2021 via Charge ID 100455610 with Others was fully satisfied on 05 Aug 2026.
Filing
Sms Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
Charges
A charge with Others amounted to Rs. 180.00 Cr with Charge ID 101242646 was registered on 24 Feb 2026.
Charges
A charge with Axis Bank Limited of Rs. 40.00 Cr registered on 22 Oct 2025 with Charge ID 101182903 was modified on 09 Jan 2026.
Charges
A charge with State Bank Of India of Rs. 173.83 Cr registered on 11 May 1989 with Charge ID 90260758 was modified on 11 Nov 2025.
Charges
A charge registered on 02 Nov 2023 via Charge ID 100819428 with Others was fully satisfied on 28 Oct 2025.
Charges
A charge with Axis Bank Limited amounted to Rs. 40.00 Cr with Charge ID 101182903 was registered on 22 Oct 2025.
AGM
Sms Pharmaceuticals Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Charges
A charge with Idbi Bank Limited of Rs. 68.00 Cr registered on 11 Nov 2014 with Charge ID 10535013 was modified on 27 Mar 2025.
Charges
A charge registered on 16 Mar 2018 via Charge ID 100161678 with Others was fully satisfied on 06 Nov 2024.
190 earlier events are in the company report.
News
Frequently asked questions
SMS Pharmaceuticals is an active public limited company based in Hyderabad, Telangana, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 14 December 1987 (39+ years old) and is registered under CIN L24239TG1987PLC008066. Listed on BSE: 532815 and NSE: SMSPHARMA.
SMS Pharmaceuticals reported revenue of ₹886.87 Cr for FY 2025-26 (up 13.3% YoY) based on consolidated financials.
SMS Pharmaceuticals has 8 current directors:
- Ramesh Babu Potluri - Managing Director
- Vamsi Krishna Potluri - Whole-Time Director
- Shravan Kudaravalli - Director
- Srinivas Sarvepalli - Director
- Suresh Kumar Gangavarapu - Director
- Shanti Sree Bolleni - Director
- Trilok Potluri - Director
- Sunkara Venkata Satya Shiva Prasad - Director
The latest financial statements of SMS Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of SMS Pharmaceuticals is 36AADCS2221D1ZX, registered in Telangana. The company has 4 GST registrations in all, of which 3 are active and 1 is cancelled or inactive. Other active GSTINs include 36AADCS2221D2ZW (Telangana), 37AADCS2221D1ZV (Andhra Pradesh).
The CIN (Corporate Identification Number) of SMS Pharmaceuticals is L24239TG1987PLC008066. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. SMS Pharmaceuticals is a listed company as per MCA records. Its shares are listed on both BSE (code: 532815) and NSE (symbol: SMSPHARMA).
SMS Pharmaceuticals has 81 court cases on record: 46 filed by the company and 35 filed against it. 11 are pending. Most are in the high courts.
SMS Pharmaceuticals was incorporated on 14 December 1987, making it 39+ years old. It is registered with the Registrar of Companies, Hyderabad.
SMS Pharmaceuticals has 52 deals on record (50 market trades, 1 acquisition, 1 ipo); the latest was in November 2025.
The peers of SMS Pharmaceuticals by revenue are Virupaksha Organics Limited, Symed Labs Limited, Synokem Pharmaceuticals Limited, Sterile India Private Limited, Prime Pharmaceuticals Private Limited and 3 more, all in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).